Editorial panying importance of H19 should both energize the heart valve research field and restore hope for clarifying an appropriate target for a pharmacologic strategy against idiopathic CAVD.
C alcific aortic valve disease (CAVD) is an age-related disorder that causes significant cardiovascular morbidity and mortality and is directly responsible for ≈15 000 patient deaths per year in the United States. Currently, the molecular mechanism by which CAVD initiates is unknown, making discovery of a nonsurgical strategy challenging. 1 Garg et al 2 made a seminal discovery in 2005 when they showed NOTCH1 mutations led to heritable CAVD. Since then, the heart valve research community has sought a causal mechanism that could connect NOTCH1 dysfunction to idiopathic CAVD. That causal link has been elusive until the recent and impressive work by Hadji et al 3 in this issue of Circulation demonstrated that the promoter region of the long noncoding (lnc) RNA H19 is hypomethylated in patients with CAVD. This hypomethylation, in turn, increases H19 expression in the valve interstitial cells (VICs), where it prevents NOTCH1 transcription by seemingly blocking or outcompeting p53's recruitment to the NOTCH1 promoter. Thus, H19 appears to be the missing link (or lncRNA, if you will) connecting NOTCH1 to idiopathic CAVD.
LncRNAs are transcripts that lack protein translation potential, but they are master regulators of gene expression and their own expression dysregulation is associated with a variety of human pathologies. H19 controls gene expression at multiple levels, from chromatin modification to direct protein inhibition, and has been labeled as the multitasking lncRNA prototype. 4 H19 expression is controlled by genomic imprinting through methylation of its promoter region, with methylation negatively regulating expression, and is typically expressed at low levels only from the maternal allele after birth. 5 In the arterial vasculature, H19 is highly expressed during development but largely absent after birth; however, it reemerges in vascular smooth muscle cells in cases of neointimal hyperplasia 6 and atherosclerosis, 7 two pathologies that share similar hallmarks with CAVD. This reemerging pattern of H19 in vascular disease is similar to some of the molecular signatures observed during fetal and postnatal development of aortic valves that also reemerge during early CAVD, 8 suggesting that CAVD may be an unwelcomed encore presentation of valve development signaling that arises because of the high mechanical demands placed on the aging valve tissue. More recently, H19 has been shown to be upregulated in patients with heart failure and a mouse model of cardiac hypertrophy, 9 further supporting its importance in cardiovascular disease pathogenesis. Clarifying the mechanism of H19 methylation will potentially identify new pharmacologic targets for slowing or preventing CAVD, which are severely lacking, 1 and possibly for treating other cardiovascular pathologies.
More important, the current finding of H19 repressing NOTCH1 should reenergize the CAVD research field. Progress in uncovering the mechanism(s) causing CAVD has been challenging on multiple levels. First, most end-stage human tissue lnc-ing NOTCH1 to idiopathic Calcific aortic Valve disease samples are so diseased and calcified that finding an early, molecular signature is nearly impossible. Second, discord exists within the valve research field regarding whether calcification occurs by an osteogenic or a dystrophic process. It is unclear whether one is the nidus for the disease because key molecules representing both are present in calcified valves, but individual researchers typically focus their studies on one process of calcification without consideration of the other. Third, the few animal models of CAVD have not allowed for detailed mechanistic studies probing the etiology, with the notable exception of the Notch1 +/mouse. 10, 11 This model has revealed many insights into the heritable form of CAVD but has heretofore been limited and viewed as disconnected from the idiopathic version of the disease. However, with the newest findings uncovered by Hadji et al 3 , the past decade of work focused on the molecular mechanism of CAVD in Notch1 +/mice can suddenly be viewed in a much wider context as likely relevant to most or all forms of CAVD.
The pathology of CAVD in Notch1 +/mice is similar to that observed in humans: thickened aortic valve leaflets and varying sized regions of calcification that result in an ≈3-fold increase in tissue stiffness compared with wild-type mice at 1 year of age. 10, 11 Last year, the first VICs from immortalized Notch1 +/animals were successfully isolated and characterized as highly enriched in the inflammatory cell-cell junction protein cadherin-11 (CDH11, also known as OB-cadherin as it was first observed in osteoblasts). 11 This enrichment in CDH11 may be a compensatory mechanism adopted by the VICs to restore some of the putative cell-cell communication that is lost because of the lack of NOTCH1; however, CDH11 is a robust cell-cell junction that is a primary driver of myofibroblast differentiation 12 and key contributor to inflammatory disease. 13 CDH11 overexpression causes CAVD in mice 14 and has been found to be upregulated in cases of human idiopathic CAVD (Figure) . 15 Additionally, Hadjj et al 3 showed that knockdown of H19 decreased CDH11 by ≈30% in human VICs cultured in osteogenic medium (online-only Data Supplement Figure 1 in Hadji et al 3 ) . Interestingly, CDH11 transcription was not increased by osteogenic medium, suggesting that H19 expression may directly affect CDH11 through repression of NOTCH1. H19 knockdown also decreased key regulators of osteogenesis BMP2, BGLAP, and RUNX2 (Figure 3 in 3 ); however, these drug targets are not ideal for CAVD because of their importance in bone homeostasis. Although only a correlate at this point, H19's repression of NOTCH1 3 may lead to CDH11 overexpression in cases of CAVD, 15 and this finding is noteworthy because CDH11 is a cell surface receptor on VICs that can likely be targeted as a novel therapy against CAVD (Figure) . 1 Multiple questions remain to be answered: How is methylation of H19 regulated? Is it genetic or caused by environmental factors? Are other genes besides NOTCH1 altered by H19 in CAVD? Regardless, the recent work by Hadji et al 3 is the most exciting discovery for heart valve research since Garg et al 2 found that NOTCH1 haploinsufficiency resulted in heritable CAVD. Further, the renewed focus on NOTCH1 and the accom- This evidence complements previous data showing that the repression of NOTCH1 leads to CAVD, likely through myofibroblast and osteogenic differentiation. Cell-cell junction protein cadherin-11 (CDH11) is of particular interest as a potential therapeutic because it is an accessible cell surface protein enriched in both murine Notch1 +/valve interstitial cells (VICs) 11 and human CAVD. 15 
